文摘
摘要目的:研究等离子体是否GFAP (pGFAP)水平与成像技术措施,可以用作预后患者血液生物标志物RIS (pwRIS)。
背景:放射检查孤立综合征(RIS)描述了人没有以前或现在MS症状特征病变在脑MRI与女士(pwm)。没有明确如何管理pwRIS以证据为基础的指导方针。成像和blood-based生物标志物进行承诺pwRIS潜在工具指导治疗决策。我们曾表明,大多数pwRIS显示高比例的白质病变(wml)展示中央静脉(CVS)和至少一个顺rim病变,慢性的成像生物标志物,活跃的wml女士(PRL)。胶质原纤维酸性蛋白(GFAP)是一个潜在的血液生物标志物的评价但是,女士pwRIS GFAP尚未研究,特别是与CVS和以“。
设计/方法:32 pwRIS接受3 t大脑和颈部脊髓磁共振成像和测量水平pGFAP HD-1 Simoa平台(Quanterix)。斯皮尔曼相关系数是用来评估的相关性。
结果:pGFAP水平相关的积极的黑洞,CVS + wml,是否使用的斯皮尔曼相关系数(p < 0.05)。
结论:这个试点研究首次证明pGFAP水平正相关的数量:黑洞,CVS + wml,是否在pwRIS。考虑到黑洞之间的关系,建立以“和疾病进展,女士pwRIS pGFAP高水平可能增加患临床女士和残疾的风险。前瞻性验证正在确认pwRIS GFAP的预后价值。
披露:施耐德博士已经收到个人薪酬在500 - 4999美元的范围为百时美施贵宝担任顾问。施耐德博士已经收到个人薪酬在500 - 4999美元的范围为诺华公司担任顾问。Brand-Arzamendi太太没有披露。蒂莫西·r·Lim没有披露。丽莎Eunyoung李没有披露。梅勒妮Guenette没有披露。Suthiphosuwan博士没有披露。Aditya Bharatha没有披露。哦收到博士个人薪酬在5000 - 9999美元的范围为罗氏公司担任顾问。博士的机构哦收到个人薪酬在5000 - 9999美元的范围为Biogen-Idec担任顾问。 Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for BMS. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD-Serono. Dr. Oh has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi-Genzyme. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Oh has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen-Idec. Dr. Oh has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi-Genzyme. The institution of Dr. Oh has received research support from Biogen-Idec. The institution of Dr. Oh has received research support from EMD-Serono. The institution of Dr. Oh has received research support from Biogen-Idec.
